English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Proteomics separates adult-type diffuse high- grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status

MPS-Authors
/persons/resource/persons230739

Bader,  Jakob Maximilian
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons78356

Mann,  Matthias
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons78384

Meissner,  Felix
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Bader, J. M., Deigendesch, N., Misch, M., Mann, M., Koch, A., & Meissner, F. (2023). Proteomics separates adult-type diffuse high- grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status. Cell Reports Medicine, 4(1): 100877. doi:10.1016/j.xcrm.2022.100877.


Cite as: https://hdl.handle.net/21.11116/0000-000D-72DD-A
Abstract
High-grade adult-type diffuse gliomas are malignant neuroepithelial tumors with poor survival rates in com-bined chemoradiotherapy. The current WHO classification is based on IDH1/2 mutational and 1p/19q code-letion status. Glioma proteome alterations remain undercharacterized despite their promise for a better mo-lecular patient stratification and therapeutic target identification. Here, we use mass spectrometry to characterize 42 formalin-fixed, paraffin-embedded (FFPE) samples from IDH-wild-type (IDHwt) gliomas, IDH-mutant (IDHmut) gliomas with and without 1p/19q codeletion, and non-neoplastic controls. Based on more than 5,500 quantified proteins and 5,000 phosphosites, gliomas separate by IDH1/2 mutational status but not by 1p/19q status. Instead, IDHmut gliomas split into two proteomic subtypes with widespread per-turbations, including aerobic/anaerobic energy metabolism. Validations with three independent glioma pro-teome datasets confirm these subgroups and link the IDHmut subtypes to the established proneural and classic/mesenchymal subtypes in IDHwt glioma. This demonstrates common phenotypic subtypes across the IDH status with potential therapeutic implications for patients with IDHmut gliomas.